SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to reports of inevitable memory price hikes from industry leaders, fueling excitement over an AI-driven memory supercycle that has sent the stock to record highs. Community discourse is polarized between bulls celebrating institutional accumulation and historic momentum, and bears warning that current valuation levels and RSI extremes signal an impending bubble burst.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after announcing a multi-year joint research agreement with Honda to advance solid-state battery technology, validating the company's tech platform with a second major OEM. The community is actively discussing the strategic significance of this partnership, comparing it to ongoing collaborations with other automotive giants while debating the path toward commercial-scale manufacturing.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention as investors anticipate a major shift in institutional demand driven by the upcoming Russell Index reconstitution, which necessitates mandatory buying from passive funds. The community is actively tracking potential catalysts, including regulatory updates and revenue performance, while discussing how these factors might counteract persistent short-selling pressure.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum driven by growing institutional interest and high expectations for upcoming Phase 3 trial data in non-small cell lung cancer (NSCLC) and the upcoming BLA filing. Community discourse is heavily focused on the stock's potential as a buyout target, with many participants viewing the current valuation as disconnected from the company's clinical progress and platform potential.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to strong demand for its fuel cell solutions as AI data centers face urgent power grid constraints. The community is actively discussing the company's massive contract backlog and its emergence as a critical backbone for AI infrastructure.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is generating significant market interest following a series of technical breakthroughs, including FDA clearance for an AI-powered gestational age tool and expanded government cloud authorizations. While community sentiment is divided between long-term investors tracking institutional backing and technical advancements, and traders wary of profit-taking pullbacks, the stock is trending as participants monitor its potential as an AI-driven platform play in the medical technology sector.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is currently driving intense community discussion following a positive CMS star rating upgrade and court ruling, fueling speculation about potential institutional interest and long-term valuation shifts. Investors are actively debating the stock's consolidation around the five-dollar psychological threshold as they monitor short interest trends and potential upcoming SaaS partnerships.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is seeing intense volatility and aggressive buy-side momentum, fueled by its low public float and strategic backing from major industry players like IonQ and Dell. Investors are currently fixated on the company's positioning as a software-centric 'picks and shovels' play in the quantum computing sector, with many discussing the potential for a short squeeze despite concerns over insider ownership and potential dilution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor optimism driven by positive clinical data for its subcutaneous Briumvi treatment and mounting speculation of a potential buyout from a major pharmaceutical player. The community is actively discussing the company's strong growth momentum, the potential for market share expansion in new indications, and the aggressive positioning of short sellers against a backdrop of institutional accumulation.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is seeing heightened investor attention as the company navigates leadership transitions and market pressure from emerging satellite internet alternatives, while shareholders debate whether the current valuation offers a compelling value play given the reliable dividend and aggressive fiber infrastructure expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Holdings, Inc. (Nasdaq: HIND)(Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said...

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (Impetis), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK...

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer...

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed...

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...

Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key...

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced its subsidiary, LiveChain, Inc. (Livechain or LICH) (OTC Markets: LICH) has executed a binding letter of intent (LOI) with Remus Capital, a...

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

Vyome Holdings Inc.

HIND Stock Rallies 70% Pre-Market Today – Find Out Why

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.17
Prev Close	$2.18
Open	$2.28
Dividend Yield	0.00%
50-Day Moving Average	$2.17
Beta	0.14
Avg. Volume	39,080.01
PE Ratio	-0.18

52-Week High	$18.60
52-Week Low	$1.75
Market Capitalization	$15.3M
EPS (Annual)	-$4.75
Price to Book	2.27
Revenue Per Employee	$17,761.89

HINDVyome Holdings Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIND News